Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME study of [14C]clesacostat in healthy males
NCT03448172Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of clesacostat in Nonalcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD), sponsored by Pfizer. Primary endpoint: Mass Balance. Started Apr 2018; status: completed.
02
Drugs
clesacostat
03
Conditions
Nonalcoholic steatohepatitis (NASH)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03448172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03448172.